WO2022190117A1 - Magnetic nanoparticles based nucleic acid extraction from biological samples for molecular diagnostics - Google Patents
Magnetic nanoparticles based nucleic acid extraction from biological samples for molecular diagnostics Download PDFInfo
- Publication number
- WO2022190117A1 WO2022190117A1 PCT/IN2022/050171 IN2022050171W WO2022190117A1 WO 2022190117 A1 WO2022190117 A1 WO 2022190117A1 IN 2022050171 W IN2022050171 W IN 2022050171W WO 2022190117 A1 WO2022190117 A1 WO 2022190117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- mnps
- magnetic nanoparticles
- lane
- extraction
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 60
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 59
- 239000002122 magnetic nanoparticle Substances 0.000 title claims abstract description 58
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 55
- 238000000605 extraction Methods 0.000 title claims abstract description 26
- 239000012472 biological sample Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 25
- 210000002966 serum Anatomy 0.000 claims abstract description 22
- 230000015556 catabolic process Effects 0.000 claims abstract description 9
- 238000006731 degradation reaction Methods 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 101710163270 Nuclease Proteins 0.000 claims abstract description 6
- 239000013060 biological fluid Substances 0.000 claims abstract description 5
- 230000003993 interaction Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012631 diagnostic technique Methods 0.000 claims abstract description 4
- 210000003296 saliva Anatomy 0.000 claims abstract description 4
- 210000002700 urine Anatomy 0.000 claims abstract description 4
- 238000002493 microarray Methods 0.000 claims abstract description 3
- 230000001404 mediated effect Effects 0.000 claims abstract 6
- 231100000481 chemical toxicant Toxicity 0.000 claims abstract 2
- 239000003440 toxic substance Substances 0.000 claims abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 8
- -1 Fe2+ cation Chemical class 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 230000021615 conjugation Effects 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 150000004696 coordination complex Chemical class 0.000 claims description 2
- 230000009881 electrostatic interaction Effects 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 11
- 229960005542 ethidium bromide Drugs 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 6
- 101800000514 Non-structural protein 4 Proteins 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 241001502567 Chikungunya virus Species 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008049 TAE buffer Substances 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 108091064355 mitochondrial RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013269 sustained drug release Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 108010046119 hemolin Proteins 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
Definitions
- the present invention relates to a method of magnetic nanoparticles (MNPs) based nucleic acid extraction from biological fluids. Moreover, the invention relates to the use of MNPs and nucleic acid complex mixture directly for molecular diagnostics of various diseases.
- MNPs magnetic nanoparticles
- nucleic acids have been extensively used in the development of various molecular biology techniques. These techniques are used to classify microorganisms and genetic predispositions, to identify various mutations and to establish their role in the resistance of antibiotics, to study phylogenetic relationships, etc. what all these approaches have in common is collecting a sample of purified nucleic acid.
- nucleic acid extraction may therefore be characterized as a series of steps to obtain samples of nucleic acid/materials of particular purity that are free of impurities and are appropriate for various downstream application steps.
- the aim of nucleic acid extraction methods is to disintegrate the cell envelope and to achieve the full removal of lipids and proteins for the processing of pure DNA and/or RNA. This primarily focused on thermal adsorption of silica membranes/beads, anion exchange chromatography, sedimentation/precipitation and the use of magnetic particles. These techniques yield initial nucleic acid samples with differing purity and concentration based on the original sample (bacteria, viruses, tissues).
- RNA contains ribosome RNA (rRNA) 80%, mitochondrial RNA (mtRNA), messenger RNA (polyadenylate in eukaryotic cells) (mRNA) 1-5%, transfer RNA (tRNA) and microRNA molecules (miRNA).
- rRNA ribosome RNA
- mtRNA mitochondrial RNA
- mRNA messenger RNA
- tRNA transfer RNA
- miRNA microRNA molecules
- concentrations of mRNA in the cells from massive numbers to just five copies per cell.
- mRNA is the preferred RNA for reverse transcription and cDNA synthesis.
- RNA molecules are vulnerable to degradation by ozone in the air; ozone is extremely reactive regardless of whether the RNA sample is liquid or solid.
- RNA is another element that plays a role in the degradation of the RNA, as it makes proton transfer possible and acts as a source of hydronium or hydroxyl ions. That's why dehydration has a beneficial role against RNA degradation.
- Nucleic acids, particularly RNA molecules are also responsive to nucleases. In RNA extraction procedures, therefore, it is important to ensure an RNase-free fraction and a means of rapidly cooling the sample.
- the methods for preparation of nucleic acid samples can be grouped into thermal extraction, solution-based methods (homemade and commercial kits), column -based methods, and ones that use magnetic particles.
- solution-based methods and especially their homemade versions, have the disadvantage that they use toxic reagents and, therefore, a fume hood is a must; moreover, precision in phase separation is difficult to achieve; the extracted nucleic acid samples are of lower purity (especially in homemade methods) compared to those obtained by column -based methods; the obtained samples have limited use - mainly for conventional PCR.
- Commercial kits and protocols albeit validated for downstream applications, do not solve the problem of reagent toxicity and subjective factors related to the person who performs the procedure.
- MNPs without any covalent modifications have been used for nucleic acid extraction.
- Conjugation of nucleic acids to be extracted comprises of coordinate bond (Fe2+ cation is directly coordinated to the N(7) atom of guanine and indirectly, through water molecules, to the 0(6) atom of guanine and phosphate groups, thus forming an octahedral coordination complex of iron) and electrostatic interaction of the PEG coated magnetic nanoparticles with nucleic acid to be extracted.
- This interaction allows the method to be independent of the type of nucleic acid to be extracted.
- this method requires minimal use of toxic reagents for extraction of nucleic acid. The process is beneficial by cutting down the labor, time and expertise needed for the extraction of nucleic acids.
- RNA/DNA as a model we have used chikungunya virus nucleic acid
- Still another object of the present invention is nucleic acid extraction from biological samples without any covalent modifications on the MNPs for interaction.
- Yet another object of the present invention is single step extraction of nucleic acid from various biological fluids.
- Still another object of the present invention is single step extraction of nucleic acids from prokaryotic and eukaryotic cells.
- Yet another object of the present invention is single step extraction of nucleic acids from nanoparticles-nucleic acid complex using physical/mechanical or chemical treatment
- Still another object of the present invention is to use these extracted nucleic acids for molecular diagnostic techniques such as Polymerase Chain Reaction (PCR), microarray, etc.
- PCR Polymerase Chain Reaction
- Yet another object of the present invention is to enhance stability of nucleic acids and preventing its degradation from nucleases during shelf storage and transport.
- the present invention describes the methodology for nucleic acid isolation by MNPs from biological fluids as well as from prokaryotic and eukaryotic cells.
- the method of the present invention requires no covalent modification for the conjugation of nucleic acid with MNPs and hence extraction of nucleic acid is not specific to the type of the nucleic acid to be extracted.
- MNPs have been synthesized according to the synthesis protocol mentioned in the filed Patent Application in Indian Patent Office (IPO).
- Application No. 201911043317 Dated 24th October 2019 (Title of the Invention: Dual Stimuli Responsive Magnetic Nanoparticles for Sustained Drug Release; Applicant: Jawaharlal Nehru University; Inventors: Bhattacharya Jaydeep, Lucas Harsh A., MondalTitas).
- the PEG coated MNPs are incubated with the lysed biological samples for extraction of nucleic acids. Moreover, this extraction method requires minimal use of toxic reagents for extraction of nucleic acid. Later on, this complex can be directly used for molecular diagnostic techniques such as PCR for detection of nucleic acid.
- MNPs-Nucleic acid complex has enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases. This can be further explored for transport and storage related problems of nucleic acids.
- FIGURE 1 Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: PCR reaction
- FIGURE 2 PCR in presence on MNPs:Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: PCR reaction Lane 4: PCR reaction with MNPs
- FIGURE 3 PCR in presence of different concentration of MNPs: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1 : PCR reaction Lane 2: PCR reaction with 25mg/mL MNPs Lane 3: PCR reaction with 12.5mg/mL MNPs Lane 4: PCR reaction with 6.25mg/mL MNPs Lane 5: PCR reaction with 3.75mg/mL MNPs Lane 6: PCR reaction with 1.5mg/mL MNPs Lane 7: PCR reaction with 0.75mg/mL MNPs Lane 8: PCR reaction with 0.375mg/mL MNPs Lane 9: PCR reaction with 0.0375mg/mL MNPs
- FIGURE 4 PCR in presence of different concentration of MNPs with additives: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: PCR reaction Lane 2: PCR reaction with 25mg/mL MNPs Lane 3: PCR reaction with 12.5mg/mL MNPs Lane 4: PCR reaction with 6.25mg/mL MNPs Lane 5: PCR reaction with 3.75mg/mL MNPs Lane 6: PCR reaction with 1.5mg/mL MNPs Lane 7: PCR reaction with 0.75mg/mL MNPs Lane 8: PCR reaction with 0.375mg/mL MNPs Lane 9: PCR reaction with 0.0375mg/mL MNPs
- FIGURE 5 MNPs based DNA isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: 10 Copy no./mL Lane 4: 10 Copy no./mL Lane 5: 10 Copy no./mL Lane 6: lOCopy no./mL Lane 7: 1 Copy no./mL
- FIGURE 6 MNPs based DNA isolation and detection from spiked saliva: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane
- FIGURE 7 MNPs based DNA isolation and detection from spiked urine: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane
- FIGURE 8 MNPs based RNA isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: Normal Serum Lane 4: Spiked Serum Lane 5: Normal Serum Lane 6: Spiked Serum
- FIGURE 9 MNPs based pseudo virus isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 2: Spiked Serum Lane 3: Spiked Serum Lane 4: Spiked Serum Lane 5: Spiked Serum Lane 6: Spiked Serum Lane 7: Spiked Serum Lane 8: Spiked Serum Lane 9: Spiked Serum Lane 10: Spiked Serum Lane 11: Spiked Serum
- MNPs have been synthesized according to the synthesis protocol mentioned in the filed Patent Application in Indian Patent Office (IPO).
- Application No. 201911043317 Dated 24th October 2019 (Title of the Invention: Dual Stimuli Responsive Magnetic Nanoparticles for Sustained Drug Release; Applicant: Jawaharlal Nehru University; Inventors: Bhattacharya Jaydeep, Lucas Harsh A., MondalTitas).
- Biological samples are pre -heated at 95oC for 5-10 minutes and then rapidly cooling at 4oC for 5-10 minutes to denature most of the protein contents present in the sample. Later on, depending on the sample type some of the mild chemical treatment or mechanical or physical melting can be done to lyse the biological components except nucleic acids of the sample.
- step 2 The complex mixture obtained in step 2 has been incubated with PEG coated MNPs (0.25 mg) for 20-30 minutes and later on centrifuged to obtain a MNPs-Nucleic acid complex.
- step 3 The complex obtained in step 3 is directly used for PCR.
- the reaction is carried out in presence of various additives such as 2.5 mM MgC12, 6 m g/m L BSA and 7.5% DMSO along with PCR components.
- EXAMPLE 1 Using CHIKV (chikungunya virus) nsp4 gene cloned in pGME-T easy cloning vector as template, thermal cycle has been performed using Bio-Rad Cl 000 Touch Thermal Cycler as follows: 1 cycle 95 o C for 5 minutes, 30 cycles 95 o C for 30 seconds, 51 o C for 30 seconds 72 o C for 30 seconds, 1 cycle 72 o C for 5 minutes and 4 o C hold.
- PCR product (243 bp) is analyzed using 2% w/v agarose gel electrophoresis (Bio Rad Gel Electrophoresis Unit) using IX TAE buffer and 0.3 pg/mL of ethidium bromide. The DNA bands were detected under UV (Bio-Rad Gel Doc System EQ) (FIGURE 1).
- PCR in presence of MNPs has been performed, where the reaction is carried in presence of various additives.
- PCR product is analyzed using 2% w/v agarose gel electrophoresis (Bio Rad Gel Electrophoresis Unit) using IX TAE buffer and 0.3 pg/mL of ethidium bromide.
- the DNA bands were detected under UV (Bio-Rad Gel Doc System EQ) (FIGURE 2, FIGURE 3, FIGURE 4).
- MNPs-Nucleic acid complex has enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases. This can be further explored for transport and storage related problems of nucleic acids.
- Table 1 Specificity, Sensitivity, Positive Predictive Value, Negative Predictive Valueof the isolation and diagnostic method.
- CHIKV nsp4 forward CGGAGAGATTTCCAGCTGTC CHIKV nsp4 reverse: ATGTTCATCCAAGTGGCACA
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Magnetic nanoparticles mediated efficient method for single step nucleic acid extraction from biological samples has been established. This has been achieved without any covalent modification of magnetic nanoparticles for the interaction with nucleic acid, without use of any high-end instrumentation as well as without the use of toxic reagents. Moreover, this MNPs- Nucleic acid complex can be directly used for the molecular diagnostic techniques such as PCR, microarray, etc. The methodology has allowed us to achieve successful extraction of nucleic acids from various biological fluids i.e., serum, saliva, urine by nearly eliminating the need of toxic chemical reagents. The process is beneficial by cutting down the labor, time and expertise needed for the extraction of nucleic acids. Furthermore, this MNPs-Nucleic acid complex has enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases. This can be further explored for transport and storage related problems of nucleic acids.
Description
TITLE OF THE INVENTION
MAGNETIC NANOPARTICLES BASED NUCLEIC ACID EXTRACTION FROM BIOLOGICAL SAMPLES FOR MOLECULAR DIAGNOSTICS
FIELD OF THE INVENTION
[1] The present invention relates to a method of magnetic nanoparticles (MNPs) based nucleic acid extraction from biological fluids. Moreover, the invention relates to the use of MNPs and nucleic acid complex mixture directly for molecular diagnostics of various diseases.
BACKGROUND OF THE INVENTION
[2] The basic properties of nucleic acids have been extensively used in the development of various molecular biology techniques. These techniques are used to classify microorganisms and genetic predispositions, to identify various mutations and to establish their role in the resistance of antibiotics, to study phylogenetic relationships, etc. what all these approaches have in common is collecting a sample of purified nucleic acid.
[3] Since the isolation of nucleic acid is a starting point for a wide variety of downstream applications, the high quality of nucleic acid isolation from the samples is a critical factor in the performance of the subsequent phases of study. Nucleic acid extraction may therefore be characterized as a series of steps to obtain samples of nucleic acid/materials of particular purity that are free of impurities and are appropriate for various downstream application steps. The aim of nucleic acid extraction methods is to disintegrate the cell envelope and to achieve the full removal of lipids and proteins for the processing of pure DNA and/or RNA. This primarily focused on thermal adsorption of silica membranes/beads, anion exchange chromatography, sedimentation/precipitation and the use of magnetic particles. These techniques yield initial nucleic acid samples with
differing purity and concentration based on the original sample (bacteria, viruses, tissues).
[4] The choice of approach - taking into account the optimum time/quality balance - depends on the intent of the research, the form of analysis, the type of nucleic acid and the expense. It is necessary to provide suitable conditions for the extraction of nucleic acid in order to prevent the degradation of nucleic acid due to oxidation by reactive oxygen species generated during in vivo respiration or, extracellularly, by mechanisms involving metal ions.
[5] What accounts for the differences between the methods for extraction of DNA and RNA is their different stability. RNA contains ribosome RNA (rRNA) 80%, mitochondrial RNA (mtRNA), messenger RNA (polyadenylate in eukaryotic cells) (mRNA) 1-5%, transfer RNA (tRNA) and microRNA molecules (miRNA). There can be varying concentrations of mRNA in the cells: from massive numbers to just five copies per cell. In fact, mRNA is the preferred RNA for reverse transcription and cDNA synthesis. RNA molecules are vulnerable to degradation by ozone in the air; ozone is extremely reactive regardless of whether the RNA sample is liquid or solid.
[6] Water is another element that plays a role in the degradation of the RNA, as it makes proton transfer possible and acts as a source of hydronium or hydroxyl ions. That's why dehydration has a beneficial role against RNA degradation. Nucleic acids, particularly RNA molecules, are also responsive to nucleases. In RNA extraction procedures, therefore, it is important to ensure an RNase-free fraction and a means of rapidly cooling the sample.
[7] The methods for preparation of nucleic acid samples can be grouped into thermal extraction, solution-based methods (homemade and commercial kits), column -based methods, and ones that use magnetic particles.
[8] As a whole, solution-based methods, and especially their homemade versions, have the disadvantage that they use toxic reagents and, therefore, a fume hood is a must; moreover, precision in phase separation is difficult to achieve; the extracted nucleic acid samples are of lower purity (especially in homemade methods) compared to those obtained by column -based methods; the obtained samples have limited use - mainly for conventional PCR. Commercial kits and protocols, albeit validated for downstream applications, do not solve the problem of reagent toxicity and subjective factors related to the person who performs the procedure.
[9] In the present invention MNPs without any covalent modifications have been used for nucleic acid extraction. Conjugation of nucleic acids to be extracted, comprises of coordinate bond (Fe2+ cation is directly coordinated to the N(7) atom of guanine and indirectly, through water molecules, to the 0(6) atom of guanine and phosphate groups, thus forming an octahedral coordination complex of iron) and electrostatic interaction of the PEG coated magnetic nanoparticles with nucleic acid to be extracted. This interaction allows the method to be independent of the type of nucleic acid to be extracted. Moreover, this method requires minimal use of toxic reagents for extraction of nucleic acid. The process is beneficial by cutting down the labor, time and expertise needed for the extraction of nucleic acids.
OBJECTS OF THE INVENTION
[10] Accordingly, it is an object of the present invention is to extract nucleic acid (RNA/DNA (as a model we have used chikungunya virus nucleic acid)) from biological samples using MNPs.
[11] Still another object of the present invention is nucleic acid extraction from biological samples without any covalent modifications on the MNPs for interaction.
[12] Yet another object of the present invention is single step extraction of nucleic acid from various biological fluids.
[13] Still another object of the present invention is single step extraction of nucleic acids from prokaryotic and eukaryotic cells.
[14] Yet another object of the present invention is single step extraction of nucleic acids from nanoparticles-nucleic acid complex using physical/mechanical or chemical treatment
[15] Still another object of the present invention is to use these extracted nucleic acids for molecular diagnostic techniques such as Polymerase Chain Reaction (PCR), microarray, etc.
[16] Yet another object of the present invention is to enhance stability of nucleic acids and preventing its degradation from nucleases during shelf storage and transport.
SUMMARY OF THE INVENTION
[17] The present invention describes the methodology for nucleic acid isolation by MNPs from biological fluids as well as from prokaryotic and eukaryotic cells. The method of the present invention requires no covalent modification for the conjugation of nucleic acid with MNPs and hence extraction of nucleic acid is not specific to the type of the nucleic acid to be extracted.
[18] In accordance to the present invention MNPs have been synthesized according to the synthesis protocol mentioned in the filed Patent Application in Indian Patent Office (IPO). Application No. 201911043317 Dated 24th October 2019 (Title of the Invention: Dual Stimuli Responsive Magnetic Nanoparticles for Sustained Drug Release; Applicant: Jawaharlal Nehru University; Inventors: Bhattacharya Jaydeep, Gandhi Harsh A., MondalTitas).
[19] According to the present invention the PEG coated MNPs are incubated with the lysed biological samples for extraction of nucleic acids. Moreover, this extraction method requires minimal use of toxic reagents for extraction of nucleic acid. Later on, this
complex can be directly used for molecular diagnostic techniques such as PCR for detection of nucleic acid.
[20] Further, MNPs-Nucleic acid complex has enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases. This can be further explored for transport and storage related problems of nucleic acids.
BRIEF DESCRIPTION OF THE DRAWINGS
[21] The present invention may be better understood and its numerous objects, features and advantages made apparent to those skilled in the art, by referring to the accompanying drawings:
[22] FIGURE 1: PCR: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: PCR reaction
[23] FIGURE 2: PCR in presence on MNPs:Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: PCR reaction Lane 4: PCR reaction with MNPs
[24] FIGURE 3: PCR in presence of different concentration of MNPs: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1 : PCR reaction Lane 2: PCR reaction with 25mg/mL MNPs Lane 3: PCR reaction with 12.5mg/mL MNPs Lane 4: PCR reaction with 6.25mg/mL MNPs Lane 5: PCR reaction with 3.75mg/mL MNPs Lane 6: PCR reaction with 1.5mg/mL MNPs Lane 7: PCR reaction with 0.75mg/mL MNPs Lane 8: PCR reaction with 0.375mg/mL MNPs Lane 9: PCR reaction with 0.0375mg/mL MNPs
[25] FIGURE 4: PCR in presence of different concentration of MNPs with additives: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: PCR reaction Lane 2: PCR reaction with 25mg/mL MNPs Lane 3: PCR reaction with 12.5mg/mL MNPs Lane 4: PCR reaction with 6.25mg/mL MNPs Lane 5:
PCR reaction with 3.75mg/mL MNPs Lane 6: PCR reaction with 1.5mg/mL MNPs Lane 7: PCR reaction with 0.75mg/mL MNPs Lane 8: PCR reaction with 0.375mg/mL MNPs Lane 9: PCR reaction with 0.0375mg/mL MNPs
[26] FIGURE 5: MNPs based DNA isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: 10 Copy no./mL Lane 4: 10 Copy no./mL Lane 5: 10 Copy no./mL Lane 6: lOCopy no./mL Lane 7: 1 Copy no./mL
[27] FIGURE 6: MNPs based DNA isolation and detection from spiked saliva: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane
1: 107 Copy no./mL Lane 2: 105 Copy no./mL Lane 3: 103 Copy no./mL Lane 4: lOCopy no./mL Lane 5 : 1 Copy no./mL
[28] FIGURE 7: MNPs based DNA isolation and detection from spiked urine: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane
1: 107 Copy no./mL Lane 2: 105 Copy no./mL Lane 3: 103 Copy no./mL Lane 4: lOCopy no./mL Lane 5 : 1 Copy no./mL
[29] FIGURE 8: MNPs based RNA isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 3: Normal Serum Lane 4: Spiked Serum Lane 5: Normal Serum Lane 6: Spiked Serum
[30] FIGURE 9: MNPs based pseudo virus isolation and detection from spiked serum: Digital image of PCR products run on 2% (w/v) agarose gel stained with ethidium bromide Lane 1: lOObp Ladder Lane 2: Spiked Serum Lane 3: Spiked Serum Lane 4: Spiked Serum Lane 5: Spiked Serum Lane 6: Spiked Serum Lane 7: Spiked Serum Lane 8: Spiked Serum Lane 9: Spiked Serum Lane 10: Spiked Serum Lane 11: Spiked Serum
DETAILED DESCRIPTION OF THE INVENTION
[31] The The aspects of the present invention are achieved by the protocol mentioned as follows:
1. Synthesis of PEG coated MNPs:
[32] MNPs have been synthesized according to the synthesis protocol mentioned in the filed Patent Application in Indian Patent Office (IPO). Application No. 201911043317 Dated 24th October 2019 (Title of the Invention: Dual Stimuli Responsive Magnetic Nanoparticles for Sustained Drug Release; Applicant: Jawaharlal Nehru University; Inventors: Bhattacharya Jaydeep, Gandhi Harsh A., MondalTitas).
2. Preparation of Biological samples:
[33] Biological samples are pre -heated at 95oC for 5-10 minutes and then rapidly cooling at 4oC for 5-10 minutes to denature most of the protein contents present in the sample. Later on, depending on the sample type some of the mild chemical treatment or mechanical or physical melting can be done to lyse the biological components except nucleic acids of the sample.
3. Incubation of synthesized PEG coated MNPs with Biological Samples:
[34] The complex mixture obtained in step 2 has been incubated with PEG coated MNPs (0.25 mg) for 20-30 minutes and later on centrifuged to obtain a MNPs-Nucleic acid complex.
4. Using MNPs-Nucleic acid complex for molecular diagnostics:
[35] The complex obtained in step 3 is directly used for PCR. For PCR reaction in presence of MNPs, the reaction is carried out in presence of various additives such as 2.5 mM MgC12, 6 m g/m L BSA and 7.5% DMSO along with PCR components.
[36] The present invention is illustrated with examples below, which should in no way be construed as limiting the invention.
[37] EXAMPLE 1
Using CHIKV (chikungunya virus) nsp4 gene cloned in pGME-T easy cloning vector as template, thermal cycle has been performed using Bio-Rad Cl 000 Touch Thermal Cycler as follows: 1 cycle 95 o C for 5 minutes, 30 cycles 95 o C for 30 seconds, 51 o C for 30 seconds 72 o C for 30 seconds, 1 cycle 72 o C for 5 minutes and 4 o C hold. PCR product (243 bp) is analyzed using 2% w/v agarose gel electrophoresis (Bio Rad Gel Electrophoresis Unit) using IX TAE buffer and 0.3 pg/mL of ethidium bromide. The DNA bands were detected under UV (Bio-Rad Gel Doc System EQ) (FIGURE 1).
[38] EXAMPLE 2
PCR in presence of MNPs has been performed, where the reaction is carried in presence of various additives. PCR product is analyzed using 2% w/v agarose gel electrophoresis (Bio Rad Gel Electrophoresis Unit) using IX TAE buffer and 0.3 pg/mL of ethidium bromide. The DNA bands were detected under UV (Bio-Rad Gel Doc System EQ) (FIGURE 2, FIGURE 3, FIGURE 4).
[39] EXAMPLE 3
Isolation and detection of DNA from spiked serum, saliva, urine is carried in presence of MNPs (FIGURE 5, FIGURE 6, FIGURE 7).
[40] EXAMPLE 4
Isolation and detection of RNA from spiked serum is carried in presence of MNPs (FIGURE 8).
[41] EXAMPLE 5
Isolation and detection of pseudo virus from spiked serum is carried in presence of MNPs (FIGURE 9).
[42] EXAMPLE 6
Specificity, Sensitivity, Positive Predictive Value, Negative Predictive Value of the isolation and diagnostic method (TABLE 1).
[43] Moreover, MNPs-Nucleic acid complex has enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases. This can be further explored for transport and storage related problems of nucleic acids.
[44] While this invention has been described in certain embodiments, the present invention can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this invention pertains and which fall within the limits of the appended claims and their equivalents.
[45] Table 1: Specificity, Sensitivity, Positive Predictive Value, Negative Predictive Valueof the isolation and diagnostic method.
[46] CHIKV nsp4 Sequence:
>gb:JF272476|Organism:Chikungunya virus|Strain Name:IND-06-Guj|Protein Name:nonstructural protein P4|Gene Symbol:nsP4
TATATATTCTCGTCGGACACTGGTCCAGGTCATTTACAACAGAAGTCAGTACG
CCAGTCAGTGCTGCCGGTGAACACCCTGGAGGAAGTCCACGAGGAGAAGTGT
TACCCACCTAAGCTGGATGAAGCAAAGGAGCAACTATTACTTAAGAAACTCC
AGGAGAGTGCATCCATGGCCAACAGAAGCAGGTATCAGTCGCGCAAAGTAG
AAAACATGAAAGCAGCAATCATCCAGAGACTAAAGAGAGGCTGTAGACTAT
ACTTAATGTCAGAGACCCCAAAAGTCCCTACTTACCGGACTACATATCCGGC
GCCTGTGTACTCGCCTCCGATCAACGTCCGATTGTCCAATCCCGAGTCCGCAG
TGGCAGCATGCAATGAGTTCTTAGCTAGAAACTATCCAACTGTCTCATCATAC
CAAATTACCGACGAGTATGATGCATATCTAGACATGGTGGACGGGTCGGAGA
GTTGCCTGGACCGAGCGACATTCAATCCGTCAAAACTCAGGAGCTACCCGAA
ACAGCACGCTTACCACGCGCCCTCCATCAGAAGCGCTGTACCGTCCCCATTCC
AGAACACACTACAGAATGTACTGGCAGCAGCCACGAAAAGAAACTGCAACG
TCACACAGATGAGGGAATTACCCACTTTGGACTCAGCAGTATTCAACGTGGA
GTGTTTCAAAAAATTCGCATGCAACCAAGAATACTGGGAAGAATTTGCTGCC
AGCCCT ATT AGG AT A AC A ACTG AG A ATTT AGC A ACCT ATGTT ACT AA ACT A A
AAGGGCCAAAAGCAGCAGCGCTATTCGCAAAAACCCATAATCTACTGCCACT
ACAGGAAGTACCAATGGATAGGTTCACAGTAGATATGAAAAGGGACGTGAA
GGTGACTCCTGGTACAAAGCATACAGAGGAAAGACCTAAGGTGCAGGTTATA
CAGGCGGCTGAACCCTTGGCGACAGCATACCTATGTGGGATTCACAGAGAGC
TGGTTAGGAGGCTGAACGCCGTCCTCCTACCCAATGTACATACACTATTTGAC
ATGTCTGCCGAGGATTTCGATGCCATCATAGCCGCACACTTTAAGCCAGGAG
ACACTGTTTTGGAAACGGACATAGCCTCCTTTGATAAGAGCCAAGATGATTC
ACTTGCGCTTACTGCTTTGATGCTGTTAGAGGATTTAGGGGTGGATCACTCCC
TGCTGGACTTGATAGAGGCTGCTTTCGGAGAGATTTCCAGCTGTCACCTACCG
ACAGGTACGCGCTTCAAGTTCGGCGCCATGATGAAATCAGGTATGTTCCTAA
CTCTGTTCGTCAACACATTGTTAAACATCACCATCGCCAGCCGAGTGCTGGAA
GATCGTCTGACAAAATCCGCGTGCGCGGCCTTCATCGGCGACGACAACATAA
TACATGGAGTCGTCTCCGATGAATTGATGGCAGCCAGATGTGCCACTTGGAT
GAACATGGAAGTGAAGATCATAGATGCAGTTGTATCCTTGAAAGCCCCTTAC
TTTTGTGGAGGGTTTATACTGCACGATACTGTGACAGGAACAGCTTGCAGAG
TGGCAGACCCGCTAAAAAGGCTTTTTAAACTGGGCAAACCGCTAGCGGCAGG
TGACGAACAAGATGAAGATAGAAGACGAGCGCTGGCTGACGAAGTGATCAG
ATGGCAACGAACAGGGCTAATTGATGAGCTGGAGAAAGCGGTATACTCTAGG
TACGAAGTGCAGGGTATATCAGTTGTGGTAATGTCCATGGCCACCTTTGCAA
GCTCCAGATCCAACTTCGAGAAGCTCAGAGGACCCGTCATAACTTTGTACGG
CGGTCCTAAA
[47] pGEM-T Easy Vector Sequence:
>pGEM-T Easy Vector
GGGCGAATTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGG
AATTCGATnATCACTAGTGAATTCGCGGCCGCCTGCAGGTCGACCATATGGGA
GAGCTCCCAACGCGTTGGATGCATAGCTTGAGTATTCTATAGTGTCACCTAAA
TAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGC
TCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGG
TGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTT
TCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGC
GGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACT
CGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTG
AGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGC
GTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCA
AGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCC
CTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATAC
CTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTG
TAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAG
TCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACA
GGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTG
GCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAAC
CACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAA
AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG
TGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGA
TCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGT
ATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCAC
CTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCG
TGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAAT
GATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAG
CCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCA
TCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAAT
AGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTC
GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACAT
GATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTT
GTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGC
ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAG
TACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTG
CCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTG
CTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCT
GTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCAT
CTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGC
CGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTC
CTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATA
CAT ATTTG A ATGTATTT AG A A A A AT A A AC A A AT AGGGGTTCCGCGC AC ATTT
CCCCGAAAAGTGCCACCTGATGCGGTGTGAAATACCGCACAGATGCGTAAGG
AGAAAATACCGCATCAGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGC
GTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCC
AGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGCTCCAACGTCAAAGGGC
GAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATC
AAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG
AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAG
GAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCG
GTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGG
GCGCGTCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTG
CGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGC
GATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGAC
GGCC AGTG A ATTGT A AT ACG ACTC ACT AT A
[48] Primer Sequence:
CHIKV nsp4 forward: CGGAGAGATTTCCAGCTGTC CHIKV nsp4 reverse: ATGTTCATCCAAGTGGCACA
Claims
CLAIMS:
1) Magnetic nanoparticles mediated single step nucleic acid extraction from biological samples.
2) The magnetic nanoparticles mediated method as claimed in claim 1, single step nucleic acid extraction from biological fluids i.e., serum, saliva, urine etc.
3) The magnetic nanoparticles mediated method as claimed in claim 1, single step nucleic acid extraction from prokaryotic and eukaryotic cells with minimal or without the use of toxic chemical reagents.
4) The magnetic nanoparticles mediated method as claimed in claim 1, claim 2 and claim 3 is devoid of any covalent modifications of the PEG coated magnetic nanoparticles for the conjugation of nucleic acids to be extracted. The interaction comprises of coordinate bond (Fe2+ cation is directly coordinated to the N(7) atom of guanine and indirectly, through water molecules, to the 0(6) atom of guanine and phosphate groups, thus forming an octahedral coordination complex of iron). Furthermore, an electrostatic interaction between the PEG coated magnetic nanoparticles with nucleic acid to be extracted also exists. The combined interactions allow the method to be independent of the type of nucleic acid to be extracted.
5) The magnetic nanoparticles mediated method as claimed in claim 1 to claim 4, the MNPs-Nucleic acid complex for direct usability in molecular diagnostic techniques i.e., PCR, microarray etc.
6) The MNPs-Nucleic acid complex as claimed in claim 5, single step nucleic acid extraction from the complex using low frequency sonication (50-60 kHz) or with the use of minimal chemical treatment.
7) The MNPs-Nucleic acid complex as claimed in claim 5, enhanced stability and shelf life compared to nucleic acid preventing its degradation from nucleases, which can be further strategized for transport and storage related problems of nucleic acids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202111009417 | 2021-03-06 | ||
IN202111009417 | 2021-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022190117A1 true WO2022190117A1 (en) | 2022-09-15 |
Family
ID=83226500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/050171 WO2022190117A1 (en) | 2021-03-06 | 2022-03-01 | Magnetic nanoparticles based nucleic acid extraction from biological samples for molecular diagnostics |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022190117A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009103018A2 (en) * | 2008-02-15 | 2009-08-20 | Life Technologies Corporation | Methods and kits for extraction of dna |
-
2022
- 2022-03-01 WO PCT/IN2022/050171 patent/WO2022190117A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009103018A2 (en) * | 2008-02-15 | 2009-08-20 | Life Technologies Corporation | Methods and kits for extraction of dna |
Non-Patent Citations (1)
Title |
---|
MIN, JI HYUN ET AL.: "Isolation of DNA using magnetic nanoparticles coated with dimercaptosuccinic acid", ANALYTICAL BIOCHEMISTRY, vol. 447, 2014, pages 114 - 118, XP028808595, DOI: 10.1016/j.ab.2013.11.018 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107022651B (en) | Kit for rapidly detecting hepatitis C virus nucleic acid and detection method thereof | |
CN110343785B (en) | Kit for detecting hepatitis B virus covalent closed circular DNA based on PCR-CRISPR-cas13a | |
WO2018133546A1 (en) | CONSTRUCTION METHOD, DETECTION METHOD AND KIT FOR NON-INVASIVE PRENATAL FETAL α-THALASSEMIA GENE MUTATION DETECTION LIBRARY | |
JPS63245698A (en) | Method and apparatus for detecting nucleic acid | |
WO2022033407A1 (en) | Product for detecting dna/rna by using nucleic acid mass spectrometry and detection method | |
CN107557461B (en) | Detection method of nucleic acid mass spectrum for early screening of liver cancer susceptibility genes | |
WO2018133547A1 (en) | METHOD FOR CONSTRUCTING LIBRARY FOR NON-INVASIVE PRENATAL FETAL β-THALASSEMIA GENE MUTATION DETECTION, DETECTION METHOD AND KIT | |
CN112322614A (en) | Kit for extracting blood genome DNA by paramagnetic particle method and use method thereof | |
TW201321520A (en) | Method and system for virus detection | |
CN117210455A (en) | Primer group, kit and method for detecting east yang virus based on LAMP method | |
WO2022190117A1 (en) | Magnetic nanoparticles based nucleic acid extraction from biological samples for molecular diagnostics | |
CN111057791A (en) | Kit for detecting HBV pgRNA in blood | |
CN114525275B (en) | Eutectic solvent applied to DNA extraction, DNA extraction method and kit | |
WO2023077722A1 (en) | Nucleic acid-methylated cytosine conversion method | |
JP2019165752A (en) | Methods for isolating nucleic acid from specimens in liquid based cytodiagnosis preservatives containing formaldehyde | |
CN111295713A (en) | Method for quantifying nucleic acid using stable isotope-labeled nucleic acid as internal standard and use thereof | |
Hegde et al. | Rapid and inexpensive method of PCR ready DNA isolation from human peripheral blood and saliva | |
US20210207125A1 (en) | Method of isolating nucleic acids for long sequencing reads | |
CN101906414B (en) | Concentration method, detection method and kit for methylated DNA | |
CN111676226B (en) | Hexavalent chromium aptamer, aptamer derivative and application thereof | |
Mauger et al. | Maximizing Yield from Plasma Circulating DNA Extraction | |
CN117512085B (en) | Primer group and kit for detecting HLA-DPB1 genotyping | |
Nina et al. | DNA Methylome Distinguishes Oropharyngeal and Oral Cancer from Oral Lesions and Healthy Oral Mucosa | |
CN116790720A (en) | CRISPR/Cas12 a-based miRNA rapid detection reagent and detection method thereof | |
CN116926167A (en) | Target nucleic acid capture probe, kit, method and application in targeted capture urine sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22766542 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22766542 Country of ref document: EP Kind code of ref document: A1 |